Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview
- Phase 1 clinical trial enrollment has been completed
- Novel approach targeting α-lactalbumin protein shows potential for breast cancer prevention
- Increased national exposure through NewsNation feature may enhance company visibility
- None.
Insights
Anixa completed Phase 1 enrollment for its breast cancer vaccine targeting α-lactalbumin, marking early development progress.
Anixa Biosciences has reached a procedural milestone by completing enrollment in the Phase 1 clinical trial for its breast cancer vaccine. This represents forward momentum in the clinical development timeline, though it's important to recognize this is just an early step in the lengthy drug development process.
The vaccine employs an interesting scientific approach, targeting α-lactalbumin - a protein uniquely expressed during lactation and in many breast cancer cells but not in normal breast tissue. This selective expression pattern creates a potential immunological window for targeting cancer cells while sparing healthy tissue, a critical factor for cancer vaccine safety.
Phase 1 trials primarily assess safety and dosing parameters rather than efficacy. The press release notably doesn't provide information about the trial size, patient demographics, or anticipated timeline for results analysis. We also don't have any preliminary safety data at this stage.
The announcement is coupled with news about media exposure on NewsNation, suggesting the company is working on two fronts: advancing its clinical program while also building market awareness. For small biotechnology companies with early-stage assets, visibility can be crucial for supporting ongoing development efforts.
In the context of cancer vaccine development, which has historically faced significant challenges in translating preclinical promise to clinical success, this represents positive but very preliminary progress. The scientific approach targeting α-lactalbumin is mechanistically sound but remains unproven in humans. The completion of enrollment enables the company to progress toward data collection, which will provide the first human evidence of the vaccine's potential.
Anixa's breast cancer vaccine is designed to train the immune system to recognize and eliminate cancerous cells before they can develop into invasive tumors. The vaccine targets a lactation protein, α-lactalbumin, which is only expressed in the breast when a woman is lactating but not at other times in her life or in other tissues. However, when a woman develops breast cancer many of the malignant cells will express α-lactalbumin. Activating the immune system, through vaccination, to direct cytotoxic T cells to the tumor cell expressing this protein may provide preemptive immune protection against emerging breast tumors that express α-lactalbumin.
"We are pleased to have our breast cancer vaccine featured on NewsNation's 'Elizabeth Vargas Reports,' as this national exposure brings greater awareness to the importance of preventative cancer immunotherapy," said Dr. Kumar. "We believe we have made significant progress in the development of this vaccine, having recently completed enrollment in the Phase 1 clinical trial. We look forward to the next stage of development and are optimistic about the impact this vaccine could have in the treatment and prevention of breast cancer."
The NewsNation "Elizabeth Vargas Reports" interview can be accessed here: https://www.newsnationnow.com/health/breast-cancer-vaccine-moving-to-critical-phase/.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-breast-cancer-vaccine-featured-in-newsnation-interview-302471341.html
SOURCE Anixa Biosciences, Inc.
FAQ
What is the mechanism of action for Anixa Biosciences (ANIX) breast cancer vaccine?
What stage of development is Anixa's (ANIX) breast cancer vaccine currently in?
How does Anixa's (ANIX) breast cancer vaccine work to prevent cancer?
What is significant about the α-lactalbumin protein targeted by Anixa's vaccine?
Where was Anixa Biosciences' (ANIX) breast cancer vaccine featured?
